Benefits and Harms of Mammography Screening in 75 + Women to Inform Shared Decision-making: a Simulation Modeling Study.

Autor: Jayasekera, Jinani, Stein, Sarah, Wilson, Oliver W. A., Wojcik, Kaitlyn M., Kamil, Dalya, Røssell, Eeva-Liisa, Abraham, Linn A., O'Meara, Ellen S., Schoenborn, Nancy Li, Schechter, Clyde B., Mandelblatt, Jeanne S., Schonberg, Mara A., Stout, Natasha K.
Předmět:
Zdroj: JGIM: Journal of General Internal Medicine; Feb2024, Vol. 39 Issue 3, p428-439, 12p
Abstrakt: Background: Guidelines recommend shared decision-making (SDM) around mammography screening for women ≥ 75 years old. Objective: To use microsimulation modeling to estimate the lifetime benefits and harms of screening women aged 75, 80, and 85 years based on their individual risk factors (family history, breast density, prior biopsy) and comorbidity level to support SDM in clinical practice. Design, Setting, and Participants: We adapted two established Cancer Intervention and Surveillance Modeling Network (CISNET) models to evaluate the remaining lifetime benefits and harms of screening U.S. women born in 1940, at decision ages 75, 80, and 85 years considering their individual risk factors and comorbidity levels. Results were summarized for average- and higher-risk women (defined as having breast cancer family history, heterogeneously dense breasts, and no prior biopsy, 5% of the population). Main Outcomes and Measures: Remaining lifetime breast cancers detected, deaths (breast cancer/other causes), false positives, and overdiagnoses for average- and higher-risk women by age and comorbidity level for screening (one or five screens) vs. no screening per 1000 women. Results: Compared to stopping, one additional screen at 75 years old resulted in six and eight more breast cancers detected (10% overdiagnoses), one and two fewer breast cancer deaths, and 52 and 59 false positives per 1000 average- and higher-risk women without comorbidities, respectively. Five additional screens over 10 years led to 23 and 31 additional breast cancer cases (29–31% overdiagnoses), four and 15 breast cancer deaths avoided, and 238 and 268 false positives per 1000 average- and higher-risk screened women without comorbidities, respectively. Screening women at older ages (80 and 85 years old) and high comorbidity levels led to fewer breast cancer deaths and a higher percentage of overdiagnoses. Conclusions: Simulation models show that continuing screening in women ≥ 75 years old results in fewer breast cancer deaths but more false positive tests and overdiagnoses. Together, clinicians and 75 + women may use model output to weigh the benefits and harms of continued screening. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: